|
|||||
Application data: |
|||||
| Registration number: | E011954 | |
| European Patent number: | EP2215124 | |
| Application number: | EP08798550.3 | |
| Filing date of the application: | 22.08.2008 | |
| Date of the grant of the European patent: | 24.02.2016 | |
| Date of the publication of the translation: | 15.07.2016 | |
| Status: | European patent validated in Estonia | |
| Fees paid for the years of validity: | 16 | |
| IPC class: | C07K 16/40 A61P 3/06 A61K 39/395 A61K 45/06 A61K 31/22 A61K 31/366 A61K 31/40 A61K 31/405 A61K 31/44 A61K 31/47 A61K 31/505 A61K 31/66 A61K 39/00 C12N 15/113 | |
| Examiner: | Reet Saarinen | |
| Owner: | Amgen Inc. | |
| Patent attorney: | Anneli Kapp | |
| Estonian title | Proproteiini konvertaasi subtilisiin-keksiini tüübiga 9 (PCSK9) seonduvad antigeeni siduvad proteiinid | |
| Translation of the patent specification: | Display translation of the patent specification | |
| Display: | EXAMINATION | DATA OF THE FEES |
|
